News

Currently marketed by Novartis for the prevention of organ rejection in kidney transplant recipients, Simulect is a monoclonal antibody that selectively blocks the receptor for interleukin-2 (IL-2), providing

The candidate was also shown to produce both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full three doses of vaccine. The phase I,

Under this agreement, Inspire will have full responsibility for the drug’s development program and regulatory filings in the US and Canada, whilst Boehringer will be responsible for supplying

In the study, PSN357 will be administered to up to 30 type 2 diabetic patients as daily doses over an initial period of 14 days. The study will

Researchers at The University of California at San Francisco and the University of Texas Southwestern Medical Center recently completed the study and reported favorable data from these trials

Approval for Multiferon in sequential combination with dacarbazine was granted based on clinical trial data that demonstrated a statistically significant advantage over untreated controls in terms of survival-without-distant-

Clinical trials for TB drugs are presently based on standard treatment regimens requiring 6-9 months of therapy, with efficacy evaluation taking another 1-2 years to measure relapse rates

The data, which was presented at the Society for Pediatric Anesthesia Meeting in Fort Myers, Florida, also showed ALGRX 3268 was well tolerated. Corgentech plans to file a

Plethora is an emerging specialty pharmaceutical company focused on the development and marketing of products for the diagnosis, treatment and management of urological disorders. Senetek is a healthcare